536 related articles for article (PubMed ID: 20595412)
1. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.
Papakostas GI; Mischoulon D; Shyu I; Alpert JE; Fava M
Am J Psychiatry; 2010 Aug; 167(8):942-8. PubMed ID: 20595412
[TBL] [Abstract][Full Text] [Related]
2. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine.
Alpert JE; Papakostas G; Mischoulon D; Worthington JJ; Petersen T; Mahal Y; Burns A; Bottiglieri T; Nierenberg AA; Fava M
J Clin Psychopharmacol; 2004 Dec; 24(6):661-4. PubMed ID: 15538131
[TBL] [Abstract][Full Text] [Related]
3. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.
Levkovitz Y; Alpert JE; Brintz CE; Mischoulon D; Papakostas GI
J Affect Disord; 2012 Feb; 136(3):1174-8. PubMed ID: 21911258
[TBL] [Abstract][Full Text] [Related]
4. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.
Levkovitz Y; Alpert JE; Brintz CE; Mischoulon D; Papakostas GI
Eur Psychiatry; 2012 Oct; 27(7):518-21. PubMed ID: 21665441
[TBL] [Abstract][Full Text] [Related]
5. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.
Sarris J; Papakostas GI; Vitolo O; Fava M; Mischoulon D
J Affect Disord; 2014 Aug; 164():76-81. PubMed ID: 24856557
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder.
Mischoulon D; Alpert JE; Arning E; Bottiglieri T; Fava M; Papakostas GI
J Clin Psychiatry; 2012 Jun; 73(6):843-8. PubMed ID: 22687580
[TBL] [Abstract][Full Text] [Related]
7. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.
Mischoulon D; Price LH; Carpenter LL; Tyrka AR; Papakostas GI; Baer L; Dording CM; Clain AJ; Durham K; Walker R; Ludington E; Fava M
J Clin Psychiatry; 2014 Apr; 75(4):370-6. PubMed ID: 24500245
[TBL] [Abstract][Full Text] [Related]
9. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
10. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
[TBL] [Abstract][Full Text] [Related]
11. SAMe and sexual functioning.
Dording CM; Mischoulon D; Shyu I; Alpert JE; Papakostas GI
Eur Psychiatry; 2012 Aug; 27(6):451-4. PubMed ID: 21398094
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.
Cooper-Kazaz R; Apter JT; Cohen R; Karagichev L; Muhammed-Moussa S; Grupper D; Drori T; Newman ME; Sackeim HA; Glaser B; Lerer B
Arch Gen Psychiatry; 2007 Jun; 64(6):679-88. PubMed ID: 17548749
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.
Lyoo IK; Yoon S; Kim TS; Hwang J; Kim JE; Won W; Bae S; Renshaw PF
Am J Psychiatry; 2012 Sep; 169(9):937-945. PubMed ID: 22864465
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
Pancheri P; Scapicchio P; Chiaie RD
Int J Neuropsychopharmacol; 2002 Dec; 5(4):287-94. PubMed ID: 12466028
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
17. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.
Gueorguieva R; Mallinckrodt C; Krystal JH
Arch Gen Psychiatry; 2011 Dec; 68(12):1227-37. PubMed ID: 22147842
[TBL] [Abstract][Full Text] [Related]
18. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
Iovieno N; Papakostas GI
J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
Delle Chiaie R; Pancheri P; Scapicchio P
Am J Clin Nutr; 2002 Nov; 76(5):1172S-6S. PubMed ID: 12418499
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
